Association of vascular endothelial growth factor (VEGF) gene polymorphism and increased serum VEGF concentration with pancreatic adenocarcinoma

Pancreatology

Volumn 13, Issue 3, 2013, Pages 267-272

  Sivaprasad, Siddapuram ^a   Govardhan, Bale ^a   Harithakrishna, Ramanujam ^a   Rao, Guduru Venkat ^a   Pradeep, Rebala ^a   Kunal, Bharadhwaj ^a   Ramakrishna, Nalla ^a   Anuradha, Shekaran ^a   Reddy, Duvvuru Nageshwar ^a  

^a ASIAN INSTITUTE OF GASTROENTEROLOGY   (India)

Author keywords

Angiogenesis; Genotypeephenotype correlation; Pancreatic cancer; Single nucleotide polymorphisms (SNPs); Vascular endothelial growth factor (VEGF)

Indexed keywords

VASCULOTROPIN;

ADULT; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84884669123     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1016/j.pan.2013.02.006     Document Type: Article

References (50)

1. Department of Epidemiology, Harvard School of Public Health, Michaud DS. Epidemiology of pancreatic cancer. Minerva Chir 2004;59:99-111.
2. Leon G, P.H, Gold EB. Epidemiology of pancreatic cancer. W J Surg 1984;8: 808-21.
3. Joseph, Fraumeni Jr JF. Cancers of the pancreas and biliary tract: epidemiological considerations. Cancer Res 1975;35:3437-46.
4. Baylor SM, Berg JW. Cross-classification and survival characteristics of 5,000 cases of cancer of the pancreas. J Surg Oncol 1973;5:335-58.
5. Dhir V, Mohandas KM. Epidemiology of digestive tract cancers in India IV. Gall bladder and pancreas. Ind J Gastroenterol 1999;18:24-8.
6. Carmeliet P, Jain RK. Association of genetic polymorphisms in the VEGF gene with breast cancer survival angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
7. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001;19:1207-25.
8. Folkman J. Angiogenesis. Annu Rev Med 2006;57:1-18.
9. Ferrante M, Pierik M, Henckaerts L, Joossens M, Claes K, Schuerbeek VN, et al. The role of vascular endothelial growth factor (VEGF) in inflammatory bowel disease. Inflamm Bowel Dis 2006;12:870-8.
10. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
11. Mattei MG, Borg JP, Rosnet O. Assignment of vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) genes to human chromosome 6p12-21 and14q24-31 regions, respectively. Genomics 1996;31:168-9.
12. Napoleone F. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002;2:795-803.
13. Chan LW, Moses MA, Goley E, Sproull M, Muanza T, Coleman CN, et al. Urinary VEGF and MMP levels as predictive markers of 1-year progression free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. J Clin Oncol 2004;22:499-506.
14. Foekens JA, Peters HA, Grebenchtchikov N, Look MP, Meijer-van GME, Geurts-Moespot A, et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 2001;61:5407-14.
15. Linderholm B, Grankvist K, Wilking N, Johansson M, Tavelin B, Henriksson R. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol 2000;18:1423-31.
16. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E. A common 936C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 2000;37:443-8.
17. Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, et al. A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer 2003;106: 468-71.
18. Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 2003;63:812-6.
19. Watson CJ, Webb NJA, Bottomley MJ, Brenchley PEC. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 2000;12:1230-5.
20. Oka N, Soeda A, Inagaki A, Onodera M, Maruyama H, Hara A, et al. VEGF promotes tumorigenesis and angiogenesis of human glioblastoma stem cells. Biochem Biophys Res Commun 2007;360:553-9.
21. Ruzzo A, Graziano F, Kawakami K, Watanabe G, Santini D, Catalano V, et al. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol 2006;24: 1883-91.
22. Lu H, Shu XO, Cui Y, Kataoka N, Wen W, Cai Q, et al. Association of genetic polymorphisms in the VEGF gene with breast cancer survival. Cancer Res 2005;65:5015-9.
23. Jin Q, Hemminki K, Enquist K, Lenner P, Grzybowska E, Klaes R, et al. Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res 2005;11:3647-53.
24. Dotor E, Cuatrecases M, Martínez-Iniesta M, Navarro M, Vilardell F, Guino E, et al. Tumor thymidylate synthase 1496d-l6 genotype as a prognostic factor in colorectal cancer patients receiving flourouracil-based adjuvant treatment. J Clin Oncol 2006;24:1603-11.
25. Talar-Wojnarowska R, Gasiorowska A, Olakowski M, Lekstan A, Lampe P, Smolarz B, et al. Vascular endothelial growth factor (VEGF) genotype and serum concentration in patients with pancreatic adenocarcinoma and chronic pancreatitis. J Physiol Pharmacol 2010;61:711-6.
26. Buchler P, Reber HA, Ullrich A, Shiroiki M, Roth M, Büchler MW, et al. Pancreatic cancer growth is inhibited by blockade of VEGF-RII. Surgery 2003;134:772-82.
27. Bruckner HW, Hrehorovich VR, Sawhney HS. Bevacizumab as treatment for chemotherapy-resistant pancreatic cancer. Anticancer Res 2005;25:3637-9.
28. Hotz HG, Hines OJ, Masood R, Hotz B, Foitzik T, Buhr HJ, et al. VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer. Surgery 2005;137:192-9.
29. Miller SA, Dykes DD, Polesky H. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
30. Zhai R, Liu G, Asomaning K, Su L, Kulke MH, Heist RS, et al. Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk. Carcinogenesis 2008;29:2330-4.
31. Heist RS, Zhai R, Liu G, Zhou W, Lin X, Su L, et al. VEGF polymorphisms and survival in early-stage non-small cell lung cancer. J Clin Oncol 2008;26:856-62.
32. Kim JG, Sohn SK, Chae YS, Cho YY, Bae HI, Yan G, et al. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with gastric cancer. Ann Oncol 2007;18:1030-6.
33. Yancopoule GD, Davis S, Gale NW. Vascular specific growth factors and blood vessel formation. Nature 2000;407:242-8.
34. Fontanini G, Faviana P, Lucchi M. A high vascular count and overexpression of vascular growth factor are associated with unfavorable prognosis in operated small cell lung cancer. Br J Cancer 2002;86:558-63.
35. Nishida N, Yano H, Komai K. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer 2004;101:1364-74.
36. Hu K, Zhang Y, Wang R, Li G, Li G, Zhang D. Current evidence on VEGF+405G/C polymorphism and malignancy susceptibility: a meta-analysis involving 30 studies. Twin Res Hum Genet 2012;15:496-502.
37. Bhanoori M, Arvind BK, Pavankumar NG, Lakshmi RK, Zondervan K, Deenadayal M, et al. The vascular endothelial growth factor (VEGF) +405G>C 50-untranslated region polymorphism and increased risk of endometriosis in South Indian women: a case control study. Hum Reprod 2005;20:1844-9.
38. Bradbury PA, Zhai R, Ma C, Xu W, Hopkins J, Kulke MJ, et al. Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis. Clin Cancer Res 2009;15:4680-5.
39. Naik NA, Bhat IA, Afroze D, Rasool R, Mir H, Andrabi SI, et al. Vascular endothelial growth factor A gene (VEGFA) polymorphisms and expression of VEGFA gene in lung cancer patients of Kashmir Valley (India). Tumour Biol 2012;33:833-9.
40. Zhai R, Liu G, Zhou W, Su L, Heist RS, Lynch TJ, et al. Vascular endothelial growth factor genotypes, haplotypes, gender and risk of non-small cell lung cancer. Clin Cancer Res 2008;14:612-7.
41. Howell WM, Bateman AC, Turner SJ, Collins A, Theaker JM. Influence of vascularendothelial growth factor single nucleotide polymorphism on tumor development in cutaneous malignant melanoma. Genes Immun 2002;3:229-32.
42. Abe A, Sato K, Habuchi T, Wang L, Li Z, Tsuchiya N, et al. Single nucleotide polymorphism in the 30 untranslated region of vascular endothelial growth factor gene in Japanese population with or without renal cell carcinoma. Tohoku J Exp Med 2002;198:181-90.
43. Lin CC, Wu HC, Tsai FJ, Chen HY, Chen WC. Vascular endothelial growth factor gene -460C/T polymorphism is a biomarker for prostate cancer. Urology 2003;62:374-7.
44. Kataoka N, Cai Q, Wen W, Shu XO, Jin F, Gao YT, et al. Population-based casecontrol study of VEGF gene polymorphisms and breast cancer risk among Chinese women. Cancer Epidemiol Biomarkers Prev 2006;15:1148-52.
45. Chae YS, Kim JG, Sohn SK, Cho YY, Ahn BM, Moon JH, et al. Association of vascular endothelial growth factor gene polymorphisms with susceptibility and clinicopathologic characteristics of colorectal cancer. J Korean Med Sci 2008;23:421-7.
46. Bae SJ, Ahn DH, Hong SP, Kang H, Hwang SG, Oh D, et al. Gender-specific association between polymorphism of vascular endothelial growth factor (VEGF 936C > T) gene and patients with stomach cancer. Yonsei Med J 2008;49:783-91.
47. Oliveira C, Lourenço GJ, Silva PM, Cardoso-Filho C, Favarelli MH, Gonçales NS, et al. Polymorphisms in the 5′ and 3′-untranslated region of the VEGF gene and sporadic breast cancer risk and clinicopathologic characteristics. Tumor Biol 2011;32:295-300.
48. Steffensen KD, Waldstrom M, Brandslund I, Jakobsen A. The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. Gynecol Oncol 2010;117:109-16.
49. Ruggiero D, Dalmasso C, Nutile T, Sorice R, Dionisi L, Aversano M, et al. Genetics of VEGF serum variation in human isolated populations of cilento: importance of VEGF polymorphisms. PLoS One 2011;6:e16982.
50. Zhai R, Gong MN, Zhou W, Thompson TB, Kraft P, Su L, et al. Genotypes and haplotypes of the VEGF gene are associated with higher mortality and lower VEGF plasma levels in patients with ARDS. Thorax 2007;62:718-22.